FY 22 Appropriations: completion nears; FY 23 Appropriations: Ready, Set, Go Part 1; Update on reconciliation.

Top-Line:

  • Analysis and Commentary describes the consequences of delay in funding the FDA.

  • FY 22 Appropriations: March 11 or Another CR?

  • FY 23 Appropriations: Ready, Set, Go.

  • Alliance campaign encourages Members of Congress to request increased FDA funding.

  • Update on Potential for Revival of Reconciliation Legislation.

  • Don’t Miss Out on the Alliance’s Budget Priorities Webinar Series With FDA Leaders.

    • Patrizia Cavazzoni, MD | CDER | April 4, 1 p.m. | Register

    • Judith McMeekin | ORA | April 6, 2 p.m. | Register

    • Susan Mayne, PhD | CFSAN | April 12, 11 a.m. | Register

    • Steven Solomon, DVM | CVM | April 22, 3 p.m. | Register

    • Jeff Shuren, MD | CDRH | April 29, 11 a.m. | Register

    • Peter Marks, MD | CBER | May 10, 1 p.m. | Register

This week’s Analysis and Commentary answers questions about the consequences of delay in FY 22 and FY 23 appropriations and in the timing for user fee reauthorization.

FY 22 Appropriations: March 11 or Another CR? When the House and Senate extended the current Continuing Resolution (CR) until March 11, it was understood that a framework existed for passing all appropriations bills by early March. Nonetheless, details have been scarce. Even now, it is not officially known what the House will be voting on during the scheduled March 9 vote.
Among the unknowns: Will the package include all twelve appropriations bills or a portion of them plus a CR for the rest? Will an omnibus include supplemental funding for Ukraine or for COVID? We will closely follow developments and report in next week’s Update on how FDA fared.

FY 23 Appropriations: Ready, Set, Go. The President delivered his State of the Union address this week, an event that traditionally kicks off the coming appropriations cycle. We expect the President’s Budget Request next, probably between March 10 and 25, though the timing is only rumored at this point. Some slippage is possible.

Beyond that, Member requests are due soon (see next story) and we expect subcommittee hearings in April. The Alliance will submit testimony to both the House and Senate Agriculture/FDA Subcommittees and encourages our members to do the same.

Alliance Campaign to Encourage Members of Congress to Request Increased FDA Funding. During March and April of each year, Members of Congress ask their constituents and interested parties to recommend program funding for the coming fiscal year. In turn, Members formulate a list of their priorities, which they share with subcommittee leadership. Requests can be highly localized (monies to rebuild a bridge) or quite global (increases for NIH).

Every year, the Alliance reaches out to Members of Congress to encourage them to tell appropriators “Increased FDA funding is one of my priorities.” We would like to broaden our efforts so Congressional offices receive 2 or 3 requests on behalf of FDA, rather than just ours.

Here is a link to last week’s Analysis and Commentary that contains more details. If you are interested in participating, please contact Roger Szemraj of the Alliance staff.

Update on Potential for Revival of Reconciliation Legislation. Senator Manchin, the primary block on Senate passage of the House-backed reconciliation bill, has started to discuss the parameters of a substantially reduced bill that he could support. It is still too early to know if this will restart the process.

We hope that even a substantially reduced bill might still have room for much-needed investment in FDA’s infrastructure. The earlier House-passed and Senate committee draft bills both included a $300 million investment, split evenly between data/technology modernizations and facility/physical improvements.

Don’t Miss Out on the Alliance’s Budget Priorities Webinar Series With FDA Leaders. Starting April 4, the Alliance will be holding an FY 23 Budget Priorities Webinar series, with presentations from the five Center Directors and the Associate Commissioner for Regulatory Affairs.

  • Patrizia Cavazzoni, MD | CDER | April 4, 1 p.m. | Register

  • Judith McMeekin | ORA | April 6, 2 p.m. | Register

  • Susan Mayne, PhD | CFSAN | April 12, 11 a.m. | Register

  • Steven Solomon, DVM | CVM | April 22, 3 p.m. | Register

  • Jeff Shuren, MD | CDRH | April 29, 11 a.m. | Register

  • Peter Marks, MD | CBER | May 10, 1 p.m. | Register

These online events are for Alliance members and media, although we welcome guests. If you are not an Alliance member and would like to participate, please contact Alliance Executive Director, Steven Grossman.

Previous
Previous

FDA Receives $102 million increase in FY 22 Omnibus. Alliance campaign encourages Members of Congress to request increased FDA funding.

Next
Next

Q&A: consequences of delay in FY 22/23 appropriations; Timing for user fee reauthorization.